Welcome to LookChem.com Sign In|Join Free

HENAN SUNLAKE ENTERPRISE CORPORATION

Free supplier Enterprise Certification

Free
supplier
8th
years

Search in the shop

  • Search in the shop
  • Search the station
Home>>Products>>540737-29-9 C16H20N6O.C6H8O7 Tofacitinib citrate

Products Categories

Product Certification&
Enterprise Certification

More Detail

HENAN SUNLAKE ENTERPRISE CORPORATION

Country: China (Mainland)

Business Type:Trading Company

Ms.summer

Tel: +86-371- 86259723

Mr.William

Tel: 17734809689

Ms.lisa

Tel: 17734809689

Ms.Tina

Tel: 86-371-86259723

Ms.Ann

Tel: 17734809689

Ms.Helen

Tel: 17734809689

Mobile: 17734809689

Tel: +86-371- 86259723

Fax: +86-371- 86259723

Province/state: HENAN

City: ZHENGZHOU

Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China

MaxCard:


qq Contact Suppliers

540737-29-9 C16H20N6O.C6H8O7 Tofacitinib citrate

CAS NO.540737-29-9

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,D/A,D/P,T/T,
Contact Supplier

Product Details

Keywords

  • BETA-OXO
  • 3-propanetricarboxylate
  • 1-Piperidinepropanenitrile

Quick Details

  • ProName: 540737-29-9 C16H20N6O.C6H8O7 Tofacit...
  • CasNo: 540737-29-9
  • Molecular Formula: C16H20N6O.C6H8O7
  • Appearance: As detailed
  • Application: 540737-29-9 ...
  • DeliveryTime: 7-10 days after payment
  • PackAge: As required
  • Port: Shanghai/Tianjin/Qingdao
  • ProductionCapacity: 100-200 Kilogram/Month
  • Purity: 99%
  • Storage: room temperatuure
  • Transportation: By air/sea/express
  • LimitNum: 1 Kilogram
  • Grade: Pharma Grade

Superiority

About Certificate

 

1.Certificate Of Analysis (COA)
2.Material Safety Data Sheet (MSDS)
3.Route of synthesis (ROS)
4.Method of Aanlysis(MOA)
5.Nuclear Magnetic Resonance(NMR)

 

About Service

 

1. Quality control, before shipment, free sample for test.
2. Prompt shipment with professional documents
3. Packing as your request, with photo before shipment
4. Mixed containers with different mixed items in one container

 

About Company

 
HenNan sunlake enterprise corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .
     Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs ,  Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East ,  Africa , South America and some other countries and areas.
    We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you  better with our high - quality products and professional team.
    We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.
     We  welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!

Details

Product Name: Tofacitinib citrate
Synonyms: 1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1);1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Tofacitinib citrate (CP-690550);Tofacitinib citrate;Tasocitinib citrate;Tasocitinib citric acid s...;Xeljanz;CP-690550 (Tofacitinib citrate)
CAS: 540737-29-9
MF: C16H20N6O.C6H8O7
MW: 504.497
EINECS:  
Product Categories: Inhibitor;Inhibitors
Mol File: 540737-29-9.mol
Tofacitinib citrate Structure
 
Tofacitinib citrate Chemical Properties
storage temp.  room temp
 
Safety Information
MSDS Information
 
 
Tofacitinib citrate Usage And Synthesis
Drug forTreatment of rheumatoid arthritis Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis , trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis ( RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine) . Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function.
In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks . Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.
The above information is edited by the Chemicalbook of Tian Ye.
Application Jak kinase inhibitor, to treat rheumatoid arthritis.
Tropsch erlotinib (477600-75-2) bulk pharmaceutical chemicals.
 
Tofacitinib citrate Preparation Products And Raw materials

 

lookchemhot productCASNew CAS Cas Database Article Data Chemical Catalog
Hot Product